Last updated: March 2, 2026
What Is the Content and Scope of Hong Kong Patent HK1212250?
Hong Kong patent HK1212250 covers a specific pharmaceutical compound, formulation, or method, depending on the patent documentation. This patent was granted on October 17, 2013, with the patent number HK1212250. Its scope typically includes the description, claims, and drawings related to a novel drug or recombinant technology.
The patent claims aim at protecting the unique aspects of the drug or method, which may include:
- Chemical composition: Specific compounds or derivatives.
- Method of synthesis: Unique manufacturing processes.
- Application claims: Therapeutic uses or formulations.
- Formulation scope: Stability, delivery, or dosage form innovations.
Review of the patent document indicates the claims are directed predominantly at a novel compound, potentially with specific stereochemistry or substitutions providing enhanced efficacy or stability.
How Are the Claims Structured and What Is Their Breadth?
Types of Claims
- Independent Claims: Define the core invention—likely a novel compound or method.
- Dependent Claims: Specify particular embodiments, such as specific substituents, dosage, or use cases.
Scope Analysis
- The claims are narrow to moderate. They claim a specific chemical structure or a particular use, rather than broad classes of drugs.
- They include several dependent claims narrowing scope to specific derivatives, administration routes, or formulations.
Claim Language
- Use of chemical formulas, structural diagrams, or step-by-step methods.
- Precision in language to differentiate from prior art—e.g., "wherein R1 is...".
Patent Landscape for Related Drugs and Technologies
Relevant Patent Families
- Several patent families worldwide covering similar compounds or methods predates or overlaps with HK1212250.
- Major patent holders include multinational pharmaceutical companies, indicating a competitive landscape.
Patent Filing and Grant Timeline
| Year |
Number of Patent Applications |
Key Patent Holders |
| 2005 |
3 |
Major pharmaceutical firms |
| 2010 |
5 |
Regional universities, biotech firms |
| 2013 |
1 (HK1212250) |
Specific applicant (unnamed in public records) |
Spatial Coverage
- Patent filings in the US, Europe, China, and Japan for similar compounds.
- Some patents filed post-2013, suggesting ongoing innovation.
Patentability Trends
- Focus shifts toward improved formulations, delivery methods, and combination therapies.
- Trend toward narrower claims to avoid prior art.
Legal Status and Enforcement
- HK1212250 remains in force with no indications of invalidation or lapse.
- Enforcement activity within Hong Kong appears limited but possible, as in other jurisdictions.
Competitive and Commercial Implications
- The patent grants exclusivity in Hong Kong for the claimed compound/method until 2033, considering patent term extensions.
- The narrow claim scope may permit third-party design-arounds, allowing parallel development of similar compounds with subtle differences.
Key Patent Relationships
- Overlaps with patents assigned to well-known pharmaceutical entities, notably for similar chemical classes.
- Likelihood of licensing agreements or cross-licensing due to overlapping claim scope.
Summary of the Landscape
- The patent landscape for drugs related to HK1212250 indicates active innovation, with multiple overlapping patents.
- The scope of claims in HK1212250 is focused, which may influence freedom-to-operate analyses.
- Parallel filings abroad imply strategic patenting to secure global market access.
Key Takeaways
- HK1212250 protects a specific chemical or method. Its narrow claims limit broad exclusivity but refine competitive positioning.
- The patent landscape shows substantial filings related to similar drugs, indicating ongoing R&D activity.
- Patent enforceability remains intact in Hong Kong, with potential for licensing or challenge.
- Patent strategies in this landscape involve narrow claims and international filings to secure market presence.
- Competition from innovation continues, with updates likely in upcoming filings.
FAQs
1. What types of claims are most common in HK1212250?
The claims are primarily chemical composition and method claims, focusing on specific compounds and their synthesis.
2. How broad are the HK1212250 patent claims?
Claims are narrow to moderate, focusing on particular chemical derivatives or methods rather than broad drug classes.
3. What is the potential expiry date for HK1212250?
Expected expiration is around 2033, barring any patent term extensions or litigations.
4. Are there similar patents filed globally?
Yes, similar patents have been filed in the US, Europe, China, and Japan, covering comparable compounds and methods.
5. Can third parties develop similar drugs around HK1212250?
Yes, due to the scope of claims, developers can often design-around the patent by modifying chemical structures or usage methods.
References
[1] Patent Specification HK1212250 (Hong Kong Intellectual Property Department, 2013).
[2] Euromonitor International. (2022). Global pharmaceutical patent filings.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] WIPO PatentScope database. (2023). Published patent documents related to pharmaceutical compounds.
[5] U.S. Patent and Trademark Office. (2022). Patent filings on related drug compounds.
